Literature DB >> 10672842

Vagal withdrawal during endoscopic retrograde cholangiopancreatography.

M Christensen1, V Rasmussen, S Schulze, J Rosenberg.   

Abstract

BACKGROUND: Patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) are at risk of developing cardiorespiratory complications, but the mechanism is still unknown. Treatment with metoprolol 2 h before the endoscopy has been shown to decrease the incidence of myocardial ischaemia during ERCP. The present study evaluated whether the endoscopic stress would decrease vagal tone and whether metoprolol given before the procedure could prevent this defence-like reaction.
METHODS: Thirty-eight patients were randomized to receive either placebo or 100 mg metoprolol 2 h before ERCP. During ERCP the patients were monitored with a Holter tape recorder. Holter tapes from 31 patients (16 receiving metoprolol) were available to analyse the ratio of the standard deviations of the RR intervals (SDRR) to the mean RR intervals (measure of vagal tone) during ERCP.
RESULTS: A decreased vagal tone during the ERCP was found, but we observed no difference between the metoprolol and the placebo group. For both groups the lowest vagal tone occurred at maximum heart rate during endoscopy. The SDRR/meanRR ratio returned towards base line for the subsequent 60 min after endoscopy.
CONCLUSIONS: The existence of a defence-like reaction ('vagal withdrawal') during ERCP has been shown. Metoprolol given 2 h before the procedure did not affect the occurrence of this phenomenon. The interaction of other periendoscopic factors is still unclear and should be studied further.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10672842     DOI: 10.1080/003655200750024605

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  1 in total

1.  A new grading system to evaluate the risk of endoscopic retrograde cholangiopancreatography.

Authors:  Ina Zuber-Jerger; Esther Endlicher; Frank Kullmann; Cornelia M Gelbmann
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.